Spike Protein Luciferase
Human Centriole and Centrosome Antibody IgG ELISA Kit |
|||
MBS039049-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Human IgG antibody Laboratories manufactures the spike protein luciferase reagents distributed by Genprice. The Spike Protein Luciferase reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Spike products are available in stock. Specificity: Spike Category: Protein Group: Luciferase
Human True insulin ELISA kit |
||
BlueGene | 1 plate of 96 wells | EUR 822 |
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human True insulin ELISA kit |
||
BlueGene | 96T | EUR 700 |
Description: ELISA |
Human True Insulin ELISA Kit |
||
MyBiosource | 10x96-Strip-Wells | EUR 6725 |
Human True Insulin ELISA Kit |
||
MyBiosource | 48-Strip-Wells | EUR 550 |
Human True Insulin ELISA Kit |
||
MyBiosource | 5x96-Strip-Wells | EUR 3420 |
Human True Insulin ELISA Kit |
||
MyBiosource | 96-Strip-Wells | EUR 765 |
Human True Insulin GENLISA ELISA |
||
Krishgen | 1 x 96 wells | EUR 286 |
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78644-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike protein of BA.4 and BA.5 variants of SARS-CoV-2 have identical mutations. In this datasheet, the spike protein of BA.4 and BA.5 are referred to as BA.4/5._x000D_The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.4/5, Omicron Variant:_x000D_Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-100 µl |
|||
78641-1 | BPS Bioscience | 100 µl | EUR 795 |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility.As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in BA.1.1 Omicron Variant:A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2 |
|||
78641-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility._x000D_As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells._x000D_Spike Mutations in BA.1.1 Omicron Variant:_x000D_A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
Luciferase Protein |
|||
abx073317-20kDa1g | Abbexa | 20 kDa; 1 g | EUR 225 |
Luciferase Protein |
|||
abx073317-2kDa1g | Abbexa | 2 kDa; 1 g | EUR 3550 |
Luciferase Protein |
|||
abx073317-5kDa1g | Abbexa | 5 kDa; 1 g | EUR 325 |
Luciferase protein (His tag) |
|||
80R-1462 | Fitzgerald | 100 ug | EUR 307 |
Description: Purified recombinant firefly Luciferase protein |
firefly Luciferase Recombinant Protein |
|||
PROTA3KBZ5 | BosterBio | 20ug | EUR 250 |
Description: Firefly Luciferase Recombinant Protein expressed in E. coli with His-tag. Sequence domain: 1-550aa. Application(s): SDS-PAGE. |
COVID-19 S Protein / (Luciferase)-(6His) VLP |
|||
VLP002 | GenTarget | 1x108 VP/ml x 200ul | EUR 455 |
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with firefly luciferase genomic material. Particles were concentrated and provided in PBS solution |
OPPA02425-5UG - Luciferase Firefly Protein |
|||
OPPA02425-5UG | Aviva Systems Biology | 5ug | EUR 70 |
renilla reniformis Luciferase Recombinant Protein |
|||
PROTP27652 | BosterBio | 10ug | EUR 241 |
Description: renilla reniformis Luciferase Recombinant Protein expressed in E. coli with His-tag. Sequence domain: 1-311aa. Application(s): SDS-PAGE, Enzyme Activity. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method). |
Luciferase Luciferin 4-Monooxygenase Firefly Recombinant Protein |
|||
PROTP08659 | BosterBio | Regular: 20ug | EUR 380.4 |
Description: Luciferase produced in E.Coli is a single, non-glycosylated polypeptide chain containing 571 amino acids (1-550 a.a.) and having a molecular mass of 62.9kDa.;Luciferase is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
Recombinant other Luciferase Firefly Protein, His, E.coli-1ug |
|||
QP10776-1ug | EnQuireBio | 1ug | EUR 186 |
Recombinant other Luciferase Firefly Protein, His, E.coli-5ug |
|||
QP10776-5ug | EnQuireBio | 5ug | EUR 241.2 |
Recombinant other Luciferase Firefly Protein, His, E.coli-1mg |
|||
QP12597-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Recombinant Photinus pyralis Luciferase protein, N-His Tag |
|||
MBS157146-005mg | MyBiosource | 0.05mg | EUR 320 |
Recombinant Photinus pyralis Luciferase protein, N-His Tag |
|||
MBS157146-01mg | MyBiosource | 0.1mg | EUR 410 |